Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 11407.51 
• Atom Count: 759 
• Residue Count: 99 
• Unique protein chains: 1

2ZGA

HIV-1 protease in complex with a dimethylallyl decorated pyrrolidine based inhibitor (hexagonal space group)

• DOI: 10.2210/pdb2ZGA/pdb

• Classification: HYDROLASE/HYDROLASE INHIBITOR
• Organism(s): Human immunodeficiency virus type 1 group M subtype B (isolate BRU/LAI)
• Expression System: Escherichia coli


• Deposited: 2008-01-21 Released: 2009-02-03 
• Deposition Author(s): Boettcher, J., Blum, A., Heine, A., Diederich, W.E., Klebe, G.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.65 Å
• R-Value Free: 0.274 
• R-Value Work: 0.224 

Literature

Two Solutions for the Same Problem: Multiple Binding Modes of Pyrrolidine-Based HIV-1 Protease Inhibitors

Blum, A., Bottcher, J., Dorr, S., Heine, A., Klebe, G., Diederich, W.E.

(2011) J.Mol.Biol. 410: 745-755

• PubMed: 21762812 
• DOI: 10.1016/j.jmb.2011.04.052
• Primary Citation of Related Structures:  
  3CKT


• PubMed Abstract: 
  

Structure-based drug design is an integral part of industrial and academic drug discovery projects. Initial lead structures are, in general, optimized in terms of affinity using iterative cycles comprising synthesis, biological evaluation, computational methods, and structural analysis. X-ray crystallography commonly suggests the existence of a single well-defined state, termed binding mode, which is generally assumed to be consistent in a series of similar ligands and therefore used for the following optimization process. During the further development of symmetrically disubstituted 3,4-amino-pyrrolidines as human immunodeficiency virus type 1 protease inhibitors, we discovered that, by modification of the P1/P1' moieties of our lead structure, the activity of the inhibitors towards the active-site mutation Ile84Val was altered, however, not being explainable with the initial underlying structure-activity relationship. The cocrystallization of the most potent derivative in complex with the human immunodeficiency virus type 1 protease surprisingly led to two different crystal forms (P2(1)2(1)2(1) and P6(1)22). Structural analysis revealed two completely different binding modes; the interaction of the pyrrolidine nitrogen atom with the catalytic aspartates remains as the only similarity. The study presented clearly demonstrates that structural biology has to escort the entire lead optimization process not to fail by an initially observed binding orientation.

---

Organizational Affiliation: 

Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Protease	A	99	Human immunodeficiency virus type 1 group M subtype B (isolate BRU/LAI)	Mutation(s): 0  Gene Names: gag-pol
Find proteins for P03367 (Human immunodeficiency virus type 1 group M subtype B (isolate BRU/LAI)) Go to UniProtKB:  P03367

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
YDP	A	(3S,4S),-3,4-Bis-[(4-carbamoyl-benzensulfonyl)-(3-methyl-but-2-enyl)-amino]-pyrrolidine C28 H37 N5 O6 S2 SNNQNFFJBMXSFD-UIOOFZCWSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
YDP	Ki: 480 nM BINDINGMOAD
YDP	Ki: 480 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.65 Å
• R-Value Free: 0.274 
• R-Value Work: 0.224 
• Space Group: P 6₁ 2 2

Unit Cell:

Length (Å)	Angle (°)
a = 62.625	α = 90.00
b = 62.625	β = 90.00
c = 82.303	γ = 120.00

Software Package:

Software Name	Purpose
HKL-2000	data scaling
SHELXL-97	refinement
SHELX	model building
PHASER	phasing
HKL-2000	data reduction
MAR345dtb	data collection

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2008-01-21 
• Released Date: 2009-02-03 
• Deposition Author(s): Boettcher, J., Blum, A., Heine, A., Diederich, W.E., Klebe, G.

Revision History 

• Version 1.0: 2009-02-03
  Type: Initial release
• Version 1.1: 2011-07-13
  Type: Version format compliance
• Version 1.2: 2011-08-10
  Type: Database references, Structure summary